Lupin has received USFDA approval for Atovaquone Oral Suspension USP, 750 mg/5 million. The drug is the generic version of GlaxoSmithKline LLC’s Mepron Oral Suspension, 750 mg/5 million. The drug is indicated for prevention and acute oral treatment of mild-to-moderate Pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole (TMP-SMX).
According to industry estimates, the oral suspension has an annual sales of approximately USD 117.4 million in the US .
Leave a Reply